Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2018-08-31 Regulatory Filings
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company to the U.S. Securities and Exchange Commission staff regarding comments on a Registration Statement on Form F-1. It addresses specific SEC comments on disclosures, financial statement footings, loss per share computations, and other regulatory compliance issues related to the company's IPO registration. The document references the Registration Statement on Form F-1, which is a filing used for securities registration, and the responses are typical of correspondence during the SEC review process. This type of document is a regulatory correspondence related to a registration statement, not the registration statement itself or a financial report. It is not an Annual Report, Earnings Release, or any other financial report type. It is a regulatory filing responding to SEC comments, which fits the category of Regulatory Filings (RNS). The document length (15,000 characters) and content confirm it is not a brief announcement or a report publication announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2018-08-31 English
AMENDMENT NO. 1 TO FORM F-1
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to Form F-1, which is a Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is related to an initial public offering (IPO) of American Depositary Shares (ADSs) by Tiziana Life Sciences plc. The document includes detailed information about the offering, the company, risk factors, financial data, and legal matters. Form F-1 is specifically used for registration statements for foreign private issuers conducting an IPO in the U.S. This type of filing is a capital markets document related to fundraising and securities registration, not a financial report, management discussion, or other categories listed. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement amendment, not just an announcement or certification, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2018-08-23 English
Regulatory Filings 2018
Regulatory Filings
2018-08-16 English
REGISTRATION STATEMENT
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for an initial public offering (IPO) of American Depositary Shares (ADSs) of Tiziana Life Sciences plc. The document includes detailed information about the offering, risk factors, financial data, management discussion, and other disclosures typical of a registration statement for securities issuance. This type of filing is related to capital raising and securities registration, which aligns with the Capital/Financing Update category. It is not an annual or quarterly report, audit report, or any other category related to financial performance reporting or governance changes. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a certification, so it is not RPA or RNS.
2018-07-26 English
Regulatory Filings 2018
Regulatory Filings
2018-05-24 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter from the company's legal counsel responding to comments from the U.S. Securities and Exchange Commission (SEC) staff regarding the company's draft registration statement on Form 20-F. It discusses accounting treatments, presentation of reserves, and amendments to the registration statement. The document references the Form 20-F draft registration statement and addresses SEC staff comments, indicating it is part of the regulatory review process. It does not contain the actual financial statements or the full report itself but is a correspondence related to the registration statement filing process. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory communications and filings that do not fit other specific categories.
2018-05-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.